The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
Open accessAbstract
Plasminogen activator-inhibitor C-1 (PAI-1) plays a critical role in the regulation of fibrinolysis, serving as the primary inhibitor of tissue-type plasminogen activator. Elevated levels of PAI-1 are a risk factor for recurrent myocardial infarction, and locally increased PAI-1 expression has been described in atherosclerotic human arteries. Recent studies have shown that the administration of angiotensin converting enzyme inhibitors reduces the risk of recurrent myocardial infarction in selected patients. Since angiotensin II (Ang II) has been reported to induce PAI-1 production in cultured astrocytes, we have hypothesized that one mechanism that may contribute to the beneficial effect of angiotensin converting enzyme inhibitors is an effect on fibrinolytic balance. In the present study, we examined the interaction of Ang II with cultured bovine aortic endothelial cells (BAECs) and the effects of this peptide on the production of PAI-1. 125I-Ang II was found to bind to BAECs in a saturable and specific manner, with an apparent Kd of 1.4 nM and Bmax of 74 fmol per mg of protein. Exposure of BAECs to Ang II induced dose-dependent increases in PAI-1 antigen in the media and in PAI-1 mRNA levels. Induction of PAI-1 mRNA expression by Ang II was not inhibited by pretreating BAECs with either Dup 753 or [Sar1, Ile8]-Ang II, agents that are known to compete effectively for binding to the two major angiotensin receptor subtypes. These data indicate that Ang II regulates the expression of PAI-1 in cultured endothelial cells and that this response is mediated via a pharmacologically distinct form of the angiotensin receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,887
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.
Thomas, P. S. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.9.5201 · Cited by 8,156
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Cambien, F., Poirier, O., Lecerf, L., Evans, A., Cambou, J.-P., Arveiler, D., Luc, G., Bard, J.-M., Bara, L., Ricard, S., et al. (1992) · Nature · doi:10.1038/359641a0 · Cited by 1,913
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Hamsten, A., Wiman, B., de Faire, U., & Blombäck, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512193132501 · Cited by 1,342
White, B. A., & Bancroft, F. C. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34158-9 · Cited by 1,288
Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor
Murphy, T. J., Alexander, R. W., Griendling, K. K., Runge, M. S., & Bernstein, K. E. (1991) · Nature · doi:10.1038/351233a0 · Cited by 1,252
Cited by
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
Self-citationPlasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease
Kohler, H. P., & Grant, P. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422406 · Cited by 806
Aldosterone in Congestive Heart Failure
Weber, K. T. (2001) · New England Journal of Medicine · doi:10.1056/nejmra000050 · Cited by 770
Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L., Kaplan, N. M., O’Connor, C. M., O’Gara, P. T., & Oparil, S. (2007) · Circulation · doi:10.1161/circulationaha.107.183885 · Cited by 757
Tissue Angiotensin and Pathobiology of Vascular Disease: A Unifying Hypothesis
Dzau, V. J. (2001) · Hypertension · doi:10.1161/01.hyp.37.4.1047 · Cited by 750
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
Abou-Ismail, M. Y., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.029 · Cited by 694
Xiao, L., & Harrison, D. G. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.013 · Cited by 545
Lüscher, T. F., & Barton, M. (1997) · Clinical Cardiology · doi:10.1002/j.1932-8737.1997.tb00006.x · Cited by 536
VAUGHAN, D. E. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01420.x · Cited by 507
Self-citationZeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
Cesari, M., Pahor, M., & Incalzi, R. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00171.x · Cited by 448
Interactions of Transforming Growth Factor-β and Angiotensin II in Renal Fibrosis
Border, W. A., & Noble, N. A. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.181 · Cited by 447
Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
Taal, M. W., & Brenner, B. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00031.x · Cited by 439
Drugs targeting the renin–angiotensin–aldosterone system
Zaman, M. A., Oparil, S., & Calhoun, D. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd873 · Cited by 439
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. (2006) · Circulation · doi:10.1161/circulationaha.106.655688 · Cited by 437
Saraff, K., Babamusta, F., Cassis, L. A., & Daugherty, A. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000085631.76095.64 · Cited by 428
The renin-angiotensin-aldosterone system: a specific target for hypertension management
Weir, M. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00103-x · Cited by 407
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Alessi, M.-C., & Juhan-Vague, I. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000242905.41404.68 · Cited by 390
Henry, B. M., Vikse, J., Benoit, S., Favaloro, E. J., & Lippi, G. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.04.027 · Cited by 383
Minireview: Primary Aldosteronism—Changing Concepts in Diagnosis and Treatment
Young, W. F. (2003) · Endocrinology · doi:10.1210/en.2003-0279 · Cited by 376
Marx, N., Bourcier, T., Sukhova, G. K., Libby, P., & Plutzky, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.546 · Cited by 362
Savoia, C., & Schiffrin, E. L. (2007) · Clinical Science · doi:10.1042/cs20060247 · Cited by 326
Bernstein, K. E., Ong, F. S., Blackwell, W.-L. B., Shah, K. H., Giani, J. F., Gonzalez-Villalobos, R. A., Shen, X. Z., & Fuchs, S. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006809 · Cited by 324
O’Brien, K. D., Shavelle, D. M., Caulfield, M. T., McDonald, T. O., Olin-Lewis, K., Otto, C. M., & Probstfield, J. L. (2002) · Circulation · doi:10.1161/01.cir.0000035655.45453.d2 · Cited by 318
Hanff, T. C., Mohareb, A. M., Giri, J., Cohen, J. B., & Chirinos, J. A. (2020) · American Journal of Hematology · doi:10.1002/ajh.25982 · Cited by 312
Kerins, D. M., Hao, Q., & Vaughan, D. E. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118312 · Cited by 304
Self-citationHow much is too much? Interleukin-6 and its signalling in atherosclerosis
Schuett, H., Luchtefeld, M., Grothusen, C., Grote, K., & Schieffer, B. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-05-0297 · Cited by 289
Role of endothelial dysfunction in insulin resistance
Hsueh, W. A., & Quiñones, M. J. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00611-8 · Cited by 276
Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1
Brown, N. J., Agirbasli, M. A., Williams, G. H., Litchfield, W. R., & Vaughan, D. E. (1998) · Hypertension · doi:10.1161/01.hyp.32.6.965 · Cited by 269
Self-citationVaughan, D. E., Rouleau, J.-L., Ridker, P. M., Arnold, J. M. O., Menapace, F. J., & Pfeffer, M. A. (1997) · Circulation · doi:10.1161/01.cir.96.2.442 · Cited by 265
Self-citationAngiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide
Berry, C., Touyz, R., Dominiczak, A. F., Webb, R. C., & Johns, D. G. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.6.h2337 · Cited by 259
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
Brown, N. J., Nakamura, S., Ma, L., Nakamura, I., Donnert, E., Freeman, M., Vaughan, D. E., & Fogo, A. B. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00277.x · Cited by 255
Self-citationShariat-Madar, Z., Mahdi, F., & Schmaier, A. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106101200 · Cited by 254
YAMAMOTO, K., TAKESHITA, K., KOJIMA, T., TAKAMATSU, J., & SAITO, H. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.11.013 · Cited by 214
The Vasculature in Prediabetes
Wasserman, D. H., Wang, T. J., & Brown, N. J. (2018) · Circulation Research · doi:10.1161/circresaha.118.311912 · Cited by 137
The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins
Blais, C., Marceau, F., Rouleau, J.-L., & Adam, A. (2000) · Peptides · doi:10.1016/s0196-9781(00)00348-x · Cited by 135
Brown, N. J., Agirbasli, M., & Vaughan, D. E. (1999) · Hypertension · doi:10.1161/01.hyp.34.2.285 · Cited by 124
Self-citationPretorius, M., Rosenbaum, D., Vaughan, D. E., & Brown, N. J. (2003) · Circulation · doi:10.1161/01.cir.0000046268.59922.a4 · Cited by 96
Self-citationEndothelial cell senescence and thrombosis: Ageing clots
Bochenek, M. L., Schütz, E., & Schäfer, K. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.09.019 · Cited by 96
Blood clots in COVID-19 patients: Simplifying the curious mystery
Biswas, S., Thakur, V., Kaur, P., Khan, A., Kulshrestha, S., & Kumar, P. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110371 · Cited by 74
Zaman, A. K. M. T., Fujii, S., Sawa, H., Goto, D., Ishimori, N., Watano, K., Kaneko, T., Furumoto, T., Sugawara, T., Sakuma, I., et al. (2001) · Circulation · doi:10.1161/01.cir.103.25.3123 · Cited by 68
Toblli, J. E., Cao, G., DeRosa, G., & Forcada, P. (2005) · Heart · doi:10.1136/hrt.2003.022707 · Cited by 47
Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic Patients
Koh, K. K., Son, J. W., Ahn, J. Y., Kim, D. S., Jin, D. K., Kim, H. S., Han, S. H., Seo, Y.-H., Chung, W.-J., Kang, W. C., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000133310.42762.25 · Cited by 45
Metadata
- Authors
- Vaughan, D. E., Lazos, S. A., & Tong, K.
- Venue
- Journal of Clinical Investigation
- Published
- 1995-03-01
- Volume
- 95
- Issue
- 3
- Pages
- 995-1001
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2163510728
- Cited by
- 530
- References
- 40
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.